ZA201504878B - Method for treating cancer based on mutation status of k-ras - Google Patents
Method for treating cancer based on mutation status of k-rasInfo
- Publication number
- ZA201504878B ZA201504878B ZA2015/04878A ZA201504878A ZA201504878B ZA 201504878 B ZA201504878 B ZA 201504878B ZA 2015/04878 A ZA2015/04878 A ZA 2015/04878A ZA 201504878 A ZA201504878 A ZA 201504878A ZA 201504878 B ZA201504878 B ZA 201504878B
- Authority
- ZA
- South Africa
- Prior art keywords
- ras
- treating cancer
- cancer based
- mutation status
- mutation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000035772 mutation Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361848793P | 2013-01-11 | 2013-01-11 | |
| US201361752417P | 2013-01-14 | 2013-01-14 | |
| US13/794,712 US20140199405A1 (en) | 2013-01-11 | 2013-03-11 | Method for treating cancer based on mutation status of k-ras |
| PCT/US2014/011097 WO2014110408A1 (en) | 2013-01-11 | 2014-01-10 | Method for treating cancer based on mutation status of k-ras |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201504878B true ZA201504878B (en) | 2016-10-26 |
Family
ID=51165319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/04878A ZA201504878B (en) | 2013-01-11 | 2015-07-07 | Method for treating cancer based on mutation status of k-ras |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140199405A1 (https=) |
| EP (1) | EP2943184A4 (https=) |
| JP (1) | JP2016506908A (https=) |
| KR (1) | KR20150103746A (https=) |
| AU (1) | AU2014205254A1 (https=) |
| BR (1) | BR112015016466A2 (https=) |
| CA (1) | CA2897581A1 (https=) |
| HK (1) | HK1217292A1 (https=) |
| IL (1) | IL239740A0 (https=) |
| MX (1) | MX2015008889A (https=) |
| WO (1) | WO2014110408A1 (https=) |
| ZA (1) | ZA201504878B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103405405A (zh) | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| KR101420445B1 (ko) | 2005-08-31 | 2014-07-16 | 아브락시스 바이오사이언스, 엘엘씨 | 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물 |
| ES2421354T3 (es) | 2006-08-11 | 2013-08-30 | Johns Hopkins University | Secuencias consenso codificantes de cánceres de mama y colorrectales humanos |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| JP5579057B2 (ja) * | 2007-06-01 | 2014-08-27 | アブラクシス バイオサイエンス， エルエルシー | 再発性癌の処置のための方法および組成物 |
| HRP20192259T1 (hr) | 2009-04-15 | 2020-03-06 | Abraxis Bioscience, Llc | Pripravci nanočestica bez priona i metode njihove proizvodnje |
| CA3051495A1 (en) | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| NZ717490A (en) | 2010-03-29 | 2017-12-22 | Abraxis Bioscience Llc | Methods of treating cancer |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| BR112012030909A2 (pt) | 2010-06-04 | 2020-08-18 | Abraxis Bioscience, Llc | métodos de tratamento de câncer pancreático |
| JP6038123B2 (ja) | 2011-04-28 | 2016-12-07 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP6216721B2 (ja) | 2011-12-14 | 2017-10-18 | アブラクシス バイオサイエンス， エルエルシー | 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用 |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| EP3369432A1 (en) | 2013-12-09 | 2018-09-05 | Targovax Asa | A peptide mixture |
| CA2947963A1 (en) | 2014-05-06 | 2015-11-12 | Targovax Asa | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| PL3998069T3 (pl) | 2015-06-29 | 2025-03-31 | Abraxis Bioscience, Llc | Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych |
| BR112019006329A2 (pt) * | 2016-10-07 | 2019-06-25 | Abraxis Bioscience Llc | métodos de tratamento de câncer do trato biliar |
| EP3444272A1 (en) * | 2017-08-17 | 2019-02-20 | International-Drug-Development-Biotech | Treatment of ck8 positive cancers in relation with k-ras gene status |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| JP7832108B2 (ja) | 2019-10-28 | 2026-03-17 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
| US20230172935A1 (en) * | 2020-05-08 | 2023-06-08 | Cardiff Oncology, Inc. | Methods of monitoring kras mutations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1853250T1 (sl) * | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| PL1913157T5 (pl) * | 2005-06-28 | 2017-09-29 | Genentech Inc | Mutacje EGFR i KRAS do prognozowania reakcji pacjenta na leczenie inhibitorem EGFR |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| AR065687A1 (es) * | 2007-03-13 | 2009-06-24 | Amgen Inc | Metodo para determinar la presencia o no de una mutacion k-ras y terapia con anticuerpos anti-egfr |
| WO2011116181A1 (en) * | 2010-03-17 | 2011-09-22 | Caris Life Sciences, Inc. | Theranostic and diagnostic methods using sparc and hsp90 |
| PL2470173T3 (pl) * | 2009-08-25 | 2016-11-30 | Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog | |
| NZ717490A (en) * | 2010-03-29 | 2017-12-22 | Abraxis Bioscience Llc | Methods of treating cancer |
| WO2011127219A1 (en) * | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| WO2011146803A1 (en) * | 2010-05-20 | 2011-11-24 | Synta Pharmaceuticals Corp. | Method of treating lung adenocarcinoma with hsp90 inhibitory compounds |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| JP6038128B2 (ja) * | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| EP2823306A4 (en) * | 2012-03-09 | 2015-11-11 | Caris Life Sciences Switzerland Holdings Gmbh | BIOMARKER COMPOSITIONS AND METHODS |
| AU2013201584A1 (en) * | 2012-03-12 | 2013-09-26 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody |
-
2013
- 2013-03-11 US US13/794,712 patent/US20140199405A1/en not_active Abandoned
-
2014
- 2014-01-10 JP JP2015552819A patent/JP2016506908A/ja active Pending
- 2014-01-10 CA CA2897581A patent/CA2897581A1/en not_active Abandoned
- 2014-01-10 WO PCT/US2014/011097 patent/WO2014110408A1/en not_active Ceased
- 2014-01-10 AU AU2014205254A patent/AU2014205254A1/en not_active Abandoned
- 2014-01-10 EP EP14738060.4A patent/EP2943184A4/en not_active Withdrawn
- 2014-01-10 MX MX2015008889A patent/MX2015008889A/es unknown
- 2014-01-10 HK HK16105270.2A patent/HK1217292A1/zh unknown
- 2014-01-10 BR BR112015016466A patent/BR112015016466A2/pt not_active Application Discontinuation
- 2014-01-10 KR KR1020157021321A patent/KR20150103746A/ko not_active Withdrawn
-
2015
- 2015-07-01 IL IL239740A patent/IL239740A0/en unknown
- 2015-07-07 ZA ZA2015/04878A patent/ZA201504878B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL239740A0 (en) | 2015-08-31 |
| BR112015016466A2 (pt) | 2017-07-11 |
| EP2943184A1 (en) | 2015-11-18 |
| KR20150103746A (ko) | 2015-09-11 |
| MX2015008889A (es) | 2015-11-13 |
| CA2897581A1 (en) | 2014-07-17 |
| AU2014205254A1 (en) | 2015-07-23 |
| JP2016506908A (ja) | 2016-03-07 |
| EP2943184A4 (en) | 2016-07-20 |
| HK1217292A1 (zh) | 2017-01-06 |
| US20140199405A1 (en) | 2014-07-17 |
| WO2014110408A1 (en) | 2014-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201504878B (en) | Method for treating cancer based on mutation status of k-ras | |
| IL288181A (en) | Cancer treatment methods | |
| IL272905A (en) | Methods of treating pancreatic cancer | |
| IL304252A (en) | Cancer treatment methods | |
| IL289947A (en) | A method for treating cancer | |
| IL237791B (en) | A method for treating cancer | |
| IL245281A0 (en) | Methods and preparations for the treatment of cancer | |
| SG11201603050TA (en) | Methods for treating cancers | |
| SG11201503893RA (en) | Method of treating cancer | |
| EP3057594A4 (en) | Method of treating cancer | |
| EP2895206A4 (en) | METHOD FOR TREATING CARCINOMA | |
| SG11201508878WA (en) | Methods of treating cancer | |
| AP2015008803A0 (en) | Methods for treating psoriasis using an anti-il-23antibody | |
| IL240688A0 (en) | Pancreatic cancer treatment methods | |
| PL3016682T3 (pl) | Sposoby leczenia nowotworu | |
| EP3074040A4 (en) | Method of treating cancer | |
| ZA201507762B (en) | Methods of treating cancer | |
| PT2836176T (pt) | Técnica para tratar presbiopia | |
| AU2013904620A0 (en) | Method of treating cancer | |
| ZA201604162B (en) | Method for treating sulfide-free minerals |